




Appendix 14: COVID -19 vaccine brand guidance for clinicians

The purpose of this document is to assist clinicians and vaccine providers in determining patient vaccine eligibility where they are expressing a preference for a specific COVID-19 vaccine – Please note that VicSIS does not accept any referrals which do not fit the criteria below.



Please note:

- *Adults under 60 years old who have had dose 1 of the AstraZeneca vaccine without any serious adverse events are recommended to have dose 2. A severe adverse event is TTS or anaphylaxis to a component of the AstraZeneca vaccine or a previous dose of the AstraZeneca vaccine.
- The AstraZeneca vaccine can be used in adults aged under 60 years where the benefits are likely to outweigh the risks for that individual and the person has made an informed decision based on an understanding of the risks and benefits.
- VicSIS does not accept referrals requesting the Pfizer vaccine for reasons not meeting the criteria above.
- For more information on referral criteria, please visit the VicSIS page on the Melbourne Vaccine Education Centre (MVEC) [website](#).
- Please see the recent [statement](#) from Australian Technical Advisory Group on Immunisation (ATAGI) and the Thrombosis and Haemostasis society of Australia and New Zealand (THANZ) on TTS and the use of the COVID-19 vaccine AstraZeneca.